ECSP109969A - Terapia especifica y medicamento que usan ligando de integrina para tratar cancer - Google Patents

Terapia especifica y medicamento que usan ligando de integrina para tratar cancer

Info

Publication number
ECSP109969A
ECSP109969A EC2010009969A ECSP109969A ECSP109969A EC SP109969 A ECSP109969 A EC SP109969A EC 2010009969 A EC2010009969 A EC 2010009969A EC SP109969 A ECSP109969 A EC SP109969A EC SP109969 A ECSP109969 A EC SP109969A
Authority
EC
Ecuador
Prior art keywords
therapy
integrine
treat cancer
product used
medicinal product
Prior art date
Application number
EC2010009969A
Other languages
English (en)
Inventor
Simon Goodman
Stefan Krueger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP109969A publication Critical patent/ECSP109969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a una terapia de combinación para tratamiento de tumores y metástasis tumoral, que comprende la administración de ligandos de integrina, preferentemente antagonistas de integrina, conjuntamente con agentes co-terapéuticos o formas de terapia que tienen eficiencia sinérgica cuando se administran consecutivamente con los ligandos, tal como agentes quimioterapéuticos y/o terapia de radiación. La terapia da por resultado un incremento potencial sinérgico del efecto de inhibición de cada producto terapéutico individual en la proliferación de células tumorales, produciendo un tratamiento más efectivo que lo encontrado al administrar un componente individual solo, concurrentemente o no en el régimen de dosis de la presente invención.
EC2010009969A 2007-07-18 2010-02-17 Terapia especifica y medicamento que usan ligando de integrina para tratar cancer ECSP109969A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07014070 2007-07-18

Publications (1)

Publication Number Publication Date
ECSP109969A true ECSP109969A (es) 2010-03-31

Family

ID=39402737

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009969A ECSP109969A (es) 2007-07-18 2010-02-17 Terapia especifica y medicamento que usan ligando de integrina para tratar cancer

Country Status (19)

Country Link
US (2) US20100069302A1 (es)
EP (4) EP2441464B1 (es)
JP (3) JP2010516645A (es)
KR (2) KR20090108713A (es)
CN (2) CN101588812A (es)
AU (2) AU2008207095B2 (es)
BR (2) BRPI0806596A2 (es)
CA (2) CA2675813A1 (es)
CO (1) CO6382135A2 (es)
DK (1) DK2101805T3 (es)
EA (2) EA017864B1 (es)
EC (1) ECSP109969A (es)
ES (2) ES2399159T3 (es)
IL (1) IL199696A0 (es)
MX (1) MX2009007597A (es)
PL (1) PL2101805T3 (es)
PT (1) PT2101805E (es)
WO (2) WO2008087025A2 (es)
ZA (1) ZA200905703B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441464B1 (en) * 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
KR20110086757A (ko) * 2008-11-20 2011-07-29 메르크 파텐트 게엠베하 암을 치료하기 위해 인테그린 리간드를 사용하는 신규한 치료요법 및 약제
CN102448497A (zh) * 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
WO2011146819A2 (en) * 2010-05-20 2011-11-24 Dmd Therapies, Llc METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
CN104884955B (zh) * 2012-12-07 2017-06-27 巴克斯特国际公司 抗‑mif抗体的细胞迁移测定方法
WO2014205179A1 (en) * 2013-06-21 2014-12-24 The General Hospital Corporation Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents
KR101579054B1 (ko) * 2014-03-26 2015-12-21 한국원자력의학원 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제
EP3194972B1 (en) * 2014-09-17 2021-04-14 Merck Patent GmbH A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
CA2966288A1 (en) * 2014-10-30 2016-05-06 Big Dna Ltd Combination therapy
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
CN105906692A (zh) * 2016-03-11 2016-08-31 李书鹏 cRGD-厄洛替尼缀合物及其制备方法
GB2554333A (en) * 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US20200271654A1 (en) * 2017-02-06 2020-08-27 Expression Pathology, Inc. Quantifying MGMT Protein For Optimal Cancer Therapy
WO2022157336A1 (en) 2021-01-22 2022-07-28 Royal College Of Surgeons In Ireland Treatment of coronavirus
KR102763598B1 (ko) * 2022-05-18 2025-02-07 한국원자력의학원 포도필로톡신 유도체를 유효성분으로 포함하는 방사선 치료 증진제

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701446A (en) 1901-12-30 1902-06-03 Lewis W Wooten Cotton-chopper.
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
WO1992010209A1 (en) 1990-12-04 1992-06-25 The Wistar Institute Of Anatomy And Biology Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
JPH10504825A (ja) 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
WO1997001540A1 (en) 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1997024122A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
CZ203898A3 (cs) 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
IL125033A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
KR20000064710A (ko) 1996-03-20 2000-11-06 제넨테크, 인코포레이티드 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
EP0951295B1 (en) * 1996-05-31 2010-06-09 The Scripps Research Institute Compositions for use in inhibiting of alpha-v-beta3 mediated angiogenesis
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
EP0946164A4 (en) 1996-10-30 2000-08-23 Merck & Co Inc INTEGRIN ANTAGONISTS
WO1998018460A1 (en) 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
WO1998025892A1 (en) 1996-12-09 1998-06-18 Eli Lilly And Company Integrin antagonists
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP1000031A4 (en) 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
AU8689798A (en) 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
JP2001514253A (ja) 1997-09-04 2001-09-11 スミスクライン・ビーチャム・コーポレイション インテグリンレセプターアンタゴニスト
AR015446A1 (es) 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AU9578798A (en) 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
CN1273529A (zh) 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
CA2315232A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
BR9907218A (pt) 1998-01-23 2000-10-24 Merck Patent Gmbh Anticorpo monoclonal anti alfav-integrina e seu uso para inibir a fixação de alfav-beta6-integrina à fibronectina
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1589145A (zh) 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
US7247619B2 (en) * 2000-05-19 2007-07-24 Univ Leland Stanford Junior Viral vectors useful in induction of humoral or cellular immunity
US6773897B2 (en) * 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
JP4660067B2 (ja) * 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
BRPI0706540A2 (pt) * 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP2441464B1 (en) * 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer

Also Published As

Publication number Publication date
CN101743013A (zh) 2010-06-16
KR20100043242A (ko) 2010-04-28
BRPI0806596A2 (pt) 2013-07-23
US20100190957A1 (en) 2010-07-29
CA2693862A1 (en) 2009-01-22
JP2014015482A (ja) 2014-01-30
WO2008087025A3 (en) 2008-12-11
EP2101805A2 (en) 2009-09-23
BRPI0813513A2 (pt) 2015-01-06
EP2441464B1 (en) 2014-04-09
JP2010516645A (ja) 2010-05-20
PL2101805T3 (pl) 2013-04-30
ZA200905703B (en) 2010-05-26
WO2009010287A3 (en) 2009-04-09
WO2008087025A2 (en) 2008-07-24
AU2008207095A1 (en) 2008-07-24
EP2578225A1 (en) 2013-04-10
CA2675813A1 (en) 2008-07-24
ES2472450T3 (es) 2014-07-01
EP2441464A1 (en) 2012-04-18
EP2101805B1 (en) 2012-11-07
AU2008207095B2 (en) 2013-08-29
WO2009010287A2 (en) 2009-01-22
CO6382135A2 (es) 2012-02-15
KR20090108713A (ko) 2009-10-16
EA201000127A1 (ru) 2010-10-29
IL199696A0 (en) 2010-04-15
EA200900912A1 (ru) 2009-12-30
US20100069302A1 (en) 2010-03-18
PT2101805E (pt) 2013-01-31
MX2009007597A (es) 2009-07-22
EA017864B1 (ru) 2013-03-29
EP2164506A2 (en) 2010-03-24
JP2010533665A (ja) 2010-10-28
DK2101805T3 (da) 2013-01-21
ES2399159T3 (es) 2013-03-26
AU2008277904A1 (en) 2009-01-22
CN101588812A (zh) 2009-11-25

Similar Documents

Publication Publication Date Title
CO6382135A2 (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
WO2007084670A8 (en) Specific therapy using integrin ligands for treating cancer
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
CY1117440T1 (el) Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido
ECSP11011552A (es) Administracion continua de cilengitida en tratamientos contra el cancer
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
MX2019003134A (es) Terapia de combinacion.
CL2022001342A1 (es) Métodos de tratamiento del cáncer de pulmón de células pequeñas con formulaciones de lurbinectedina
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2022005664A (es) Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer.
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2024003563A (es) Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa.
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
WO2007082742A8 (en) Isolated organ perfusion combination therapy of cancer
NZ760040A (en) Methods of treating brain tumors using combination therapy
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
IN2015DN01496A (es)
CY1120669T1 (el) Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας
RU2014150506A (ru) Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг